• PBR Life Sciences secures USD 1M in pre-seed funding to innovate healthcare big data solutions across Africa.
• The company aims to enhance research and diagnostics by offering anonymized, AI-driven healthcare data.
• This funding positions PBR Life Sciences as a key player in transforming Africa’s healthcare landscape.

A Bold Step for African Healthcare

PBR Life Sciences, a Kenyan-based health-tech company, has raised USD 1 million in pre-seed funding to expand its healthcare big data services. The funding round aims to support the company’s African market expansion, offering its AI-driven platform to anonymize patient data.

“This investment strengthens our ability to focus on profitability while extending our reach in Africa and beyond.”

Ayodeji Alaran, PBR Life Sciences CEO

The startup leverages artificial intelligence to aggregate and anonymize healthcare data, ensuring privacy compliance while providing actionable insights. Its competitors, such as Helium Health and mPharma, primarily focus on digitizing medical records and supply chain management. 

PBR Life Sciences has an edge on the competition in the niche domain of anonymized big data for large-scale analytics. The company’s technology has already attracted attention for its potential to bridge the gap in healthcare data availability across Africa.

Transforming Data into Better Healthcare

Africa’s healthcare system faces significant challenges, including fragmented data and limited access to quality insights. With 20% of the global disease burden but only 3% of the world’s health workers, the need for efficient solutions is urgent.

PBR Life Sciences’ platform addresses this by providing anonymized, scalable, and secure healthcare data for stakeholders across the spectrum, from research institutions to government bodies. This aligns with WHO’s goals for improving data-driven healthcare in underserved regions.

This innovation could lead to better disease management strategies and improved healthcare outcomes for millions. The USD 1 million funding underscores the market’s confidence in PBR’s vision and its ability to disrupt the status quo.

A Catalyst for Health-Tech Transformation

PBR Life Sciences’ next steps include scaling its data infrastructure and forging partnerships with healthcare providers, research institutions, and governments. By 2026, the company aims to cover over 15 African countries, providing crucial insights to drive disease prevention, personalized medicine, and public health policies.

This innovation offers profound social impact. PBR is poised to empower stakeholders with better tools for patient care, research breakthroughs, and policy-making.

As the African health-tech sector grows, PBR Life Sciences has positioned itself as a critical player in a USD 60 billion industry expected to double by 2030. With its AI-driven approach and a strong foundation of investor confidence, the company has laid the groundwork to lead Africa’s health-tech revolution.